Back to search

Article

LAG3-PD1 or CTLA4-PD1 Inhibition in Advanced Melanoma: Indirect Cross Comparisons of the CheckMate-067 and RELATIVITY-047 Trials

2022-06-08

Abstract excerpt

OBJECTIVE To compare the inhibition of lymphocyte-activation gene 3 (LAG3) plus programmed cell death 1 (PD-1) versus the inhibition of cytotoxic T-lymphocyte antigen 4 (CTLA-4) plus PD-1 in patients with previously untreated advanced melanoma. DESIGN A meta-analysis of individual participant data (IPD). DATA SOURCES PubMed, Web of Science and Embase were searched from January 1, 2015, to January 14, 2022, for eli...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
aaa868ff-a850-5b6f-b9d6-2ef757be2e8a
DOI
10.21203/rs.3.rs-1726466/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
LAG3-PD1 or CTLA4-PD1 Inhibition in Advanced Melanoma: Indirect Cross Comparisons of the CheckMate-067 and RELATIVITY-047 TrialsDOI 10.21203/rs.3.rs-1726466/v1
Lead-in therapy targeting PD1 and/or LAG3 imposes distinct immune phenotypes in first-line treatment of metastatic melanomaSemantic proximity
A retrospective study of anti-PD-1 combined with temozolomide adjuvant therapy for stage III resected acral melanomaSemantic proximity
Long-term survival after neoadjuvant low-dose ipilimumab plus high-dose nivolumab in resectable stage III melanoma: the 5-year survival-update and biomarker analysis from the PRADO-trialSemantic proximity
A real-world study of adjuvant anti-PD -1 immunotherapy on stage III melanoma with BRAF, NRAS, and KIT mutations.Semantic proximity
Immune checkpoint inhibitors efficacy across solid cancers and the utility of PD-L1 as a biomarker of response: a systematic review and meta-analysisSemantic proximity
Association of NRAS mutations and tertiary lymphoid structure formation with clinical outcomes of adjuvant PD-1 inhibitors for acral melanoma.Semantic proximity
Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma.Semantic proximity
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.Semantic proximity
Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 studySemantic proximity
Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: a propensity score matched survival analysis.Semantic proximity
Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis.Semantic proximity
WITHDRAWN: Circadian Clock-Gene Structure Couples with PD-L1 Across Six Cancer Types and Defines Survival-Associated Subtypes in MelanomaSemantic proximity
Select a neighboring publication to make it the new centre.